Creo Medical

Creo Medical, headquartered in GB, is committed to reducing its environmental impact. The company aims to achieve net-zero across its Scope 1 and Scope 2 emissions by 2027. Furthermore, Creo Medical has adopted a target for a minimum annual emissions reduction of 7% across all scopes, running from 2023 to 2030.

For the reporting year 2025, Creo Medical reported Scope 2 emissions of approximately 47,600 kg CO2e and Scope 3 emissions from business travel amounting to approximately 835,200 kg CO2e. Scope 1 emissions for this year were not reported.

In 2024, Scope 2 emissions were approximately 63,900 kg CO2e, with Scope 3 business travel emissions at approximately 672,600 kg CO2e. Scope 1 emissions were reported as 0.0 kg CO2e.

The most recent available breakdown for Scope 1 emissions was in 2023, totalling approximately 207,400 kg CO2e, primarily from mobile combustion. Scope 2 emissions in 2023 included approximately 67,300 kg CO2e from purchased electricity, and Scope 3 business travel emissions were approximately 263,700 kg CO2e.

Creo Medical's environmental reporting indicates that data for Scope 3 purchased goods and services was missing for the 2023, 2024, and 2025 reporting periods. For the 2022 and 2021 reporting years, no emissions data was disclosed.

Creo Medical's emissions data is not cascaded from a parent organisation.